PLAT and ischemic stroke: Recombinant tissue-type plasminogen activator (rtPA) is the only FDA-approved thrombolytic agent for acute ischemic stroke, yet its clinical utility is constrained by a narrow therapeutic time window, rapid clearance, and hemorrhagic transformation risk.